Sun Yat-sen Memorial Hospital Seeks Transfer of Rheumatoid Arthritis Joint Destruction Prediction Patent for RMB 50,000

Recently, Sun Yat-sen Memorial Hospital of Sun Yat-sen University released“A System for Predicting One-Year Progression of Joint Destruction in Patients with Rheumatoid Arthritis”Public Notice on the Assignment of Ownership of Invention Patents. The proposed transfer price for this transaction50,000 yuan. The core of this patent isWorld’s First Construction of the “Optimized Synovial Cell Immunological Score (O-CISS)” Using Synovium-Related Immunopathological Markers, through a multi-combinatorial quantitative scoring system based on eight cellular markers including CD90 and CD3, high-risk patients for joint destruction in rheumatoid arthritis can be accurately identified one year in advance. This approach addresses the limitations of traditional clinical and serological indicators, which often yield ambiguous predictions, and provides innovative technical support for precision disease management and reduced disability rates. This patent is primarily led byDai Lie and His TeamR&D.

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized primarily by progressive joint destruction. Its pathogenesis is closely linked to synovial inflammation triggered by autoimmune dysregulation, which gradually leads to erosion of articular cartilage and bone damage, ultimately resulting in physical dysfunction or even disability. As a highly prevalent autoimmune disorder in China, RA not only inflicts persistent physical and psychological suffering on patients but also imposes a substantial burden of direct medical costs and indirect socioeconomic losses. Therefore, early and precise intervention to halt the progression of joint destruction has become a central goal of clinical treatment.

Currently, clinical prediction of the progression of joint destruction in rheumatoid arthritis (RA) mainly relies onClinical Features, Genetics, Serology, and ImagingFour major categories of indicators exist, yet each category has significant limitations. Regarding clinical features, although certain factors are considered associated with risk, the lack of unified quantitative standards makes it difficult to establish clear criteria for judgment. Genetic indicators, while supported by relevant studies, suffer from insufficient predictive specificity and cannot serve as a reliable standalone basis. Among serological indicators, routine inflammatory markers are prone to interference from various systemic factors, resulting in poor stability; furthermore, the limited clinical adoption of certain specific biomarkers hinders their widespread application. Although imaging indicators can reflect certain pathological changes, they struggle to accurately predict the risk of joint destruction progression well in advance. In addition, existing scoring systems have notable shortcomings: some exhibit inadequate predictive performance, leading to missed or misdiagnoses; while other techniques with higher precision are difficult to promote and popularize in primary care settings due to their high costs.

The core limitation of existing approaches lies in the ambiguous predictive value of single indicators and the difficulty in scientifically quantifying the combined effects of multiple factors. This prevents clinicians from accurately identifying patients at high risk for progressive joint destruction, thereby hindering the implementation of targeted, individualized intensive therapy. Furthermore, rheumatoid arthritis (RA) is characterized by significant heterogeneity, with substantial variation in disease progression rates among patients; some may experience rapid joint destruction within a short period, while others maintain a relatively stable disease course.

Therefore, there is an urgent clinical need for a highly accurate, user-friendly, and cost-effective prediction tool capable of identifying the risk of joint destruction progression in patients with rheumatoid arthritis (RA) in advance. Such a tool would facilitate timely intensified treatment for high-risk patients while avoiding overtreatment in low-risk patients, ultimately achieving precision medicine for RA, reducing disability rates, and alleviating both patient suffering and the societal healthcare burden.

The core advantages and innovations of this patented technology are primarily reflected inIndicator Construction, Predictive Performance, Practicality, and Clinical ValueFour Major Dimensions Achieve Technological Breakthroughs in Predicting the Progression of Joint Destruction in Rheumatoid Arthritis: In Terms of Indicator Innovation, We Propose for the First Time“Optimized Synovial Cell Immunology Score (O-CISS)”This core assessment system overcomes the limitations of traditional single indicators or ambiguous risk factors. By selecting eight immunopathological markers associated with synovial inflammation and joint destruction, including CD90, CD3, and CD15, we innovatively combined them to form seven optimized scoring schemes (O-CISS1–O-CISS7). This approach not only incorporates markers directly related to disease progression, such as CD90+ fibroblast-like synoviocytes and CD20+ B cells, but also creatively integrates auxiliary markers like CD3 and CD15, significantly improving prediction accuracy and addressing the industry pain point that single-marker synovial testing fails to predict effectively.

InPredictive Performanceabove, the system demonstrates performance far superior to existing solutionsPrecision and Foresight. Validated in 92 clinical samples, the AUC values of the seven optimized scores ranged from 0.764 to 0.812, with O-CISS7 achieving the highest AUC (0.812), significantly outperforming the Krenn immune synovitis score (AUC 0.668). The positive predictive values ranged from 56.4% to 93.3%, and the negative predictive values from 78.9% to 86.2%, enabling precise stratification of high-risk and low-risk patients one year in advance. After multivariate adjustment for sex, age, disease duration, and other factors, each 1-point increase in the O-CISS score was associated with a 0.430- to 0.933-fold increase in the risk of joint destruction progression, indicating a clear risk direction. Furthermore, two flexible assessment modes are supported: either any single O-CISS score can be used independently, or a combination criterion defining high risk as having three or more of the seven scores above threshold can be applied, thereby further enhancing clinical applicability.

InPracticalityOn the technical front, the solution takes into accountEconomic Efficiency and Operability, which addresses the difficulty in promoting existing precision prediction technologies. AdoptingConventional Immunohistochemical Staining Combined with Semi-Quantitative Scoring Method, the operational procedure is well-established and does not require specialized, expensive equipment, making it easier to popularize across medical institutions at all levels compared to high-cost technologies such as NanoString gene testing; the scoring criteria are clear, with scores ranging from 0 to 3 based on the extent of positive cell infiltration, yielding objective and reproducible results that lower the threshold for clinical application.

InClinical Value, this proposal constructs“Precision Screening – Targeted Intervention”closed loop, drivingRA Treatment: Transitioning from “Broad-Spectrum Therapy” to “Precision Medicine”By identifying high-risk patients one year in advance, clinicians can develop personalized, intensified treatment plans to effectively reduce or halt the progression of joint destruction and lower disability rates. Furthermore, early patient stratification helps avoid overtreatment of low-risk patients and reduces the waste of medical resources. This approach is of great significance for improving patients’ quality of life and controlling healthcare costs, offering substantial clinical value as well as socioeconomic benefits.

In summary, this patented technology centers on the Optimized Cellular Immunological Scoring System (O‑CISS) as its core innovation, achieving key breakthroughs in predicting joint destruction progression in rheumatoid arthritis across four dimensions: metric construction, predictive performance, practicality, and clinical value. It enables early and precise stratification of high-risk and low-risk patients, combining high accuracy, ease of operation, and broad applicability. This provides an important tool for precision diagnosis and treatment of RA, demonstrating strong potential for clinical translation and market adoption.

Patents and products for predicting the progression of joint destruction in patients with rheumatoid arthritis (RA) serve as a critical link between precise diagnosis and treatment of RA. Their core value lies in leveraging technological innovation to enable “early prediction and early intervention,” thereby assisting clinicians in identifying high-risk patients and formulating personalized treatment plans to reduce the risk of joint deformity and disability. Such inventions and products not only fill the gap in traditional diagnosis and treatment, where “risk is difficult to quantify and intervention is hard to precision-target,” but also drive the transformation of RA management from “empirical treatment” to “precision-based care,” holding significant importance for improving patients’ quality of life and alleviating the societal burden of healthcare costs.

From the perspective of existing technological pathways and product forms, related patents and products are mainly divided into three categories, forming a landscape where “technologies under development” coexist with “marketed products”:The first category comprises diagnostic products based on serological markers., such products areDetection of Specific Antibodies or Inflammatory Factorscentered on technologies with high maturity and strong clinical adoption. For instance, the commercially available anti-mutated citrullinated vimentin (MCV) antibody detection kit quantifies serum anti-MCV antibody levels via enzyme-linked immunosorbent assay (ELISA). Clinical studies have confirmed that a positive result serves as an independent risk factor for one-year radiographic progression of joints in patients with rheumatoid arthritis (RA). This assay is currently used for auxiliary risk assessment in the rheumatology and immunology departments of numerous tertiary hospitals across China. Additionally, the anti-cyclic citrullinated peptide (CCP) antibody detection kit, a classic tool for RA diagnosis and prognosis evaluation, is primarily employed for disease diagnosis but can also indirectly indicate the risk of joint destruction through antibody titers. It has become a routine test in primary care hospitals.

The second category is a prediction system based on the integration of imaging and AI., such technologies are based onVisual Assessmentcentered on high precision but with strong dependence on equipment. Marketed products, such as the joint ultrasound synovitis scoring system, assist in assessing the risk of progressive joint damage by quantifying indicators like synovial thickening and blood flow signals; they are currently widely used in rheumatology and immunology outpatient departments of tertiary hospitals. Additionally, MRI-based bone marrow edema assessment modules can be integrated into existing hospital imaging equipment to predict the risk of joint damage over 1–5 years by analyzing the severity of bone marrow edema, and clinical applications have already been implemented in some regional medical centers. Patented technologies under development focus more on optimizing AI algorithms.

The third category comprises detection technologies based on synovial immune or molecular markers., such technologies are based onPrecision Targetinghas been a focal point of R&D in recent years. In addition to the “Optimized Synovial Cell Immunology Scoring System (O-CISS)” being transferred in this transaction, there are also patented synovial gene detection technologies under development. For instance, Nanostring technology is used to detect the expression levels of lymphoid and myeloid lineage-related genes in synovial tissue to construct predictive models. Although these models offer high accuracy, their high testing costs currently limit their use to clinical research in a few research-oriented hospitals. Furthermore, there are patented products based on flow cytometric analysis of synovial cells, which assist in risk assessment by measuring the expression levels of cell markers such as CD90 and CD20; these products are currently in the transitional phase from laboratory validation to clinical translation.

In summary, the market size will continue to expand alongside the upgrading of diagnostic and treatment demands, thereby indirectly promoting the precise use of rheumatoid arthritis (RA) therapeutic drugs and reducing economic waste caused by overmedicalization. Patents and products for predicting the progression of joint destruction in RA patients are a crucial component of the precision diagnosis and treatment system for RA, with their development characterized by “parallel multi-technological pathways and tiered fulfillment of clinical needs.”

Currently, serological testing products have achieved widespread application, AI-powered imaging systems are gradually becoming ubiquitous, and synovial immune-related technologies are at a critical stage of translation. In the future, with continuous technological optimization, cost reduction, and support from medical insurance policies, these patents and products will further break down application barriers. Moreover, they will provide a replicable technical paradigm for the precision management of autoimmune diseases, demonstrating significant clinical, social, and commercial value.